In men with metastatic castration-resistant prostate cancer (mCRPC), the addition of Radium-233 (Ra233) (Xofigo, Bayer) to enzalutamide (Xtandi, Astellas Oncology/Pfizer Oncology) improves both radiological progression-free survival (rPFS) and overall survival (OS), according to an interim analysis of a multinational phase 3 trial. The study results were reported at the 2024 Congress of the European Society for Medical Oncology (abstract LBA1).
In a trial for which rPFS was the primary end